23 Jul, 2026
According to Straits Research, the global colorectal cancer screening market size was valued at $16.1 billion in 2025 and is estimated to reach $36 billion by 2034, growing at a CAGR of 8% during the forecast period 2026–2034.
The colorectal cancer screening market is shifting toward non-invasive methods, such as faecal immunochemical tests (FIT), stool DNA tests, and emerging blood-based assays, which offer convenience, at-home use, and higher patient acceptance compared to traditional colonoscopy, whose invasiveness, preparation, and cost limit compliance. Growing awareness and educational programs led by governments, healthcare organisations, and nonprofits are improving understanding of colorectal cancer risks, reducing stigma, and encouraging routine screening, which boosts early detection and leads to better outcomes. Lifestyle and environmental factors, including diets high in red and processed meats, low fibre, alcohol consumption, sedentary behaviour, obesity, smoking, and exposure to pollutants or occupational hazards, are increasing cancer prevalence and driving demand for screening.
However, sampling errors and tumour heterogeneity can limit the accuracy and reliability of the test. Meanwhile, advances in imaging technologies, such as CT, MRI, and PET scans, combined with AI and machine learning, enhance diagnostic precision, support early intervention, enable personalised treatment, and improve overall patient outcomes, presenting significant market opportunities.
sales@straitsresearch.com